WO2009004654A3 - Modified release dosage form of sulfonylurea compound - Google Patents

Modified release dosage form of sulfonylurea compound Download PDF

Info

Publication number
WO2009004654A3
WO2009004654A3 PCT/IS2008/000015 IS2008000015W WO2009004654A3 WO 2009004654 A3 WO2009004654 A3 WO 2009004654A3 IS 2008000015 W IS2008000015 W IS 2008000015W WO 2009004654 A3 WO2009004654 A3 WO 2009004654A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbonate
dosage form
release dosage
sulfonylurea compound
modified release
Prior art date
Application number
PCT/IS2008/000015
Other languages
French (fr)
Other versions
WO2009004654A2 (en
Inventor
Gudmundur Jens Bjarnason
Original Assignee
Actavis Group Ptc Ehf
Gudmundur Jens Bjarnason
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actavis Group Ptc Ehf, Gudmundur Jens Bjarnason filed Critical Actavis Group Ptc Ehf
Publication of WO2009004654A2 publication Critical patent/WO2009004654A2/en
Publication of WO2009004654A3 publication Critical patent/WO2009004654A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

A sustained release dosage form comprising a sulfonylurea compound, preferably, gliclazide, or pharmaceutically acceptable salt thereof as active ingredient. The dosage form comprises water-swellable polymer, a pH modifier selected from sodium hydrogen carbonate, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, magnesium carbonate, and calcium carbonate, a diluent modifier selected from mannitol and microcrystallised cellulose, and preferably as well a sparingly soluble or non-soluble diluent such as calcium hydrogen phosphate.
PCT/IS2008/000015 2007-07-02 2008-07-02 Modified release dosage form of sulfonylurea compound WO2009004654A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IS8660A IS8660A (en) 2007-07-02 2007-07-02 Glycoside pharmaceutical composition
IS8660 2007-07-02

Publications (2)

Publication Number Publication Date
WO2009004654A2 WO2009004654A2 (en) 2009-01-08
WO2009004654A3 true WO2009004654A3 (en) 2009-02-26

Family

ID=40042546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IS2008/000015 WO2009004654A2 (en) 2007-07-02 2008-07-02 Modified release dosage form of sulfonylurea compound

Country Status (2)

Country Link
IS (1) IS8660A (en)
WO (1) WO2009004654A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200704897A1 (en) * 2007-07-13 2009-02-23 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Glyclazide formulations providing extended release @

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US6720005B1 (en) * 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
WO2005041962A1 (en) * 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
WO2006030303A1 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Oral extended release dosage form comprising a high dose biguanide and a low dose sulfonylurea
WO2006123213A1 (en) * 2005-05-18 2006-11-23 Ranbaxy Laboratories Limited Modified release formulations of gliclazide
WO2007026864A1 (en) * 2005-09-01 2007-03-08 Eisai R & D Management Co., Ltd. Method for preparation of pharmaceutical composition having improved disintegradability

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US6720005B1 (en) * 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
WO2005041962A1 (en) * 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester
WO2006030303A1 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Oral extended release dosage form comprising a high dose biguanide and a low dose sulfonylurea
WO2006123213A1 (en) * 2005-05-18 2006-11-23 Ranbaxy Laboratories Limited Modified release formulations of gliclazide
WO2007026864A1 (en) * 2005-09-01 2007-03-08 Eisai R & D Management Co., Ltd. Method for preparation of pharmaceutical composition having improved disintegradability

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAMZAD ET AL: "Development of a controlled release low dose class II drug-Glipizide", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 312, no. 1-2, 7 April 2006 (2006-04-07), pages 24 - 32, XP005341521, ISSN: 0378-5173 *

Also Published As

Publication number Publication date
WO2009004654A2 (en) 2009-01-08
IS8660A (en) 2009-01-03

Similar Documents

Publication Publication Date Title
WO2006121941A3 (en) Pharmaceutical compositions comprising imatinib and a release retardant
TW200744588A (en) Pharmaceutical composition for external use
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
WO2008114800A3 (en) Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidinyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile
SG152240A1 (en) Pharmaceutical compositions comprising an amphiphilic starch
WO2005082414A3 (en) Concomitant drugs of a sulfonamide and another therapeutic agent
WO2007036952A3 (en) Novel sustained release dosage form
MA30064B1 (en) PROLONGED RELEASE FORMULATION COMPRISING OCTREOTIDE AND TWO COPOLYMERS OF POLYLACTIDE-GLYCOLIDE OR MORE
WO2008052033A3 (en) Ibuprofen composition
MX2010006241A (en) Aminotriazole derivatives as alx agonists.
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2007086078A3 (en) Novel pharmaceutical compositions and process of preparation thereof
EP1619180A4 (en) CaSR ANTAGONIST
WO2006097943A3 (en) Pharmaceutical compositions of amlodipine and benazepril
WO2007134158A3 (en) Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy
WO2006008173A3 (en) Pharmaceutical formulations for inhalation
TW200730176A (en) Formulations of quinolinones
WO2007030153A3 (en) Compositions containing micronized tanaproget
EP1935417A4 (en) Composition for use in prevention of hypoglycemic condition
UA95274C2 (en) Solid pharmaceutical composition comprising irbesartan and processes for the manufacture thereof
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
WO2009004654A3 (en) Modified release dosage form of sulfonylurea compound
WO2008022745A8 (en) Formulations for the controlled release of agrochemical active agents
WO2007054139A3 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
WO2007035816A3 (en) Paroxetine compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08763760

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08763760

Country of ref document: EP

Kind code of ref document: A2